Monitoring Survivin Expression in Cancer: Implications for Prognosis and Therapy
- 3 August 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Molecular Diagnosis & Therapy
- Vol. 17 (6), 331-342
- https://doi.org/10.1007/s40291-013-0048-1
Abstract
No abstract availableKeywords
This publication has 105 references indexed in Scilit:
- Prognostic and Clinicopathological Significance of Survivin in Colorectal Cancer: A Meta-AnalysisPLOS ONE, 2013
- Classification, Functions, and Clinical Relevance of Extracellular VesiclesPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2012
- pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevantBritish Journal of Cancer, 2012
- Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian CancerClinical Cancer Research, 2011
- Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugsBritish Journal of Cancer, 2010
- Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol ResistanceClinical Cancer Research, 2009
- The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancersBritish Journal of Cancer, 2008
- Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancerBritish Journal of Cancer, 2008
- Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinicCancer Treatment Reviews, 2007
- Validating survivin as a cancer therapeutic targetNature Reviews Cancer, 2003